These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 12768511

  • 1. [Memantine].
    Molinuevo JL.
    Neurologia; 2003 Jun; 18(5):255-61. PubMed ID: 12768511
    [Abstract] [Full Text] [Related]

  • 2. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A, Alfaro V.
    Rev Neurol; 2003 Jun; 42(10):607-16. PubMed ID: 16703529
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL, Lladó Plarrumaní A.
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [Abstract] [Full Text] [Related]

  • 4. Alzheimer's disease and the glutamate NMDA receptor.
    Doraiswamy PM.
    Psychopharmacol Bull; 2003 Dec; 37(2):41-9. PubMed ID: 14566213
    [Abstract] [Full Text] [Related]

  • 5. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL.
    J Clin Psychiatry; 2006 Dec; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [Abstract] [Full Text] [Related]

  • 6. [New therapeutic possibilities with low-affinity NMDA receptor antagonists].
    Kornhuber J, Weller M.
    Nervenarzt; 1996 Jan; 67(1):77-82. PubMed ID: 8676993
    [Abstract] [Full Text] [Related]

  • 7. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
    Parsons CG, Stöffler A, Danysz W.
    Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591
    [Abstract] [Full Text] [Related]

  • 8. Memantine: pharmacological properties and clinical uses.
    Kumar S.
    Neurol India; 2004 Sep; 52(3):307-9. PubMed ID: 15472417
    [Abstract] [Full Text] [Related]

  • 9. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
    Danysz W, Parsons CG.
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
    [Abstract] [Full Text] [Related]

  • 10. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H, Grossberg GT.
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [Abstract] [Full Text] [Related]

  • 11. Memantine: an antiglutamatergic option for dementia.
    Molinuevo JL, Garcia-Gil V, Villar A.
    Am J Alzheimers Dis Other Demen; 2004 Jul; 19(1):10-8. PubMed ID: 15002339
    [Abstract] [Full Text] [Related]

  • 12. Mechanism of action of memantine.
    Johnson JW, Kotermanski SE.
    Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
    [Abstract] [Full Text] [Related]

  • 13. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
    Song MS, Rauw G, Baker GB, Kar S.
    Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
    [Abstract] [Full Text] [Related]

  • 14. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN.
    J Clin Psychiatry; 2006 Nov; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [Abstract] [Full Text] [Related]

  • 15. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA.
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [Abstract] [Full Text] [Related]

  • 16. [Advanced dementia in Alzheimer's disease and memantine].
    Alberca R.
    Rev Neurol; 2004 Dec; 40(3):173-9. PubMed ID: 15750904
    [Abstract] [Full Text] [Related]

  • 17. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia.
    Müller WE, Mutschler E, Riederer P.
    Pharmacopsychiatry; 1995 Jul; 28(4):113-24. PubMed ID: 7491365
    [Abstract] [Full Text] [Related]

  • 18. [Memantine: from the original brand to generics].
    Titova NV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017 Jul; 117(10):136-143. PubMed ID: 29171502
    [Abstract] [Full Text] [Related]

  • 19. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
    Olin JT, Bhatnagar V, Reyes P, Koumaras B, Meng X, Brannan S.
    Int J Geriatr Psychiatry; 2010 Apr; 25(4):419-26. PubMed ID: 19670390
    [Abstract] [Full Text] [Related]

  • 20. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK, Kaul CL, Ramarao P.
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.